Have type 2 diabetes and take blood pressure meds? This blood pressure drug may increase kidney damage risk 33%

by DailyHealthPost Editorial

A widely prescribed class of blood pressure medications, dihydropyridine calcium-channel blockers (DCCBs), may be associated with an increased risk of kidney damage in individuals with type 2 diabetes, even when they are already on kidney-protective treatments. This finding, presented at the European Renal Association’s annual congress, raises important questions about current treatment strategies for diabetic kidney disease (DKD).

Key Takeaways

  • Dihydropyridine calcium-channel blockers (DCCBs), commonly used for blood pressure control, may increase kidney damage risk in type 2 diabetes patients.
  • Patients on DCCBs alongside standard kidney-protective therapies (RAS inhibitors and SGLT2 inhibitors) showed a 33% higher risk of major adverse kidney events.
  • The mechanism may involve DCCBs altering blood flow dynamics within the kidneys, potentially increasing pressure.
  • Researchers emphasize the need for further studies to confirm these findings and guide treatment decisions.

Understanding the Risk

Diabetic kidney disease (DKD) is a significant complication of type 2 diabetes, often leading to kidney failure. Managing blood pressure is crucial in slowing its progression. For years, renin-angiotensin system (RAS) inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors have been cornerstones of DKD treatment, offering substantial kidney protection.

However, the new research, which analyzed data from over 31,000 adults with type 2 diabetes between 2016 and 2021, suggests that adding DCCBs to these standard therapies might counteract some of their benefits. Patients taking DCCBs in addition to RAS and SGLT2 inhibitors experienced a 33% higher risk of major adverse kidney events, defined as a significant drop in kidney filtration capacity or progression to end-stage kidney disease requiring dialysis or transplantation.

Advertisement

Potential Mechanisms and Future Directions

Researchers hypothesize that DCCBs might contribute to kidney damage by preferentially relaxing the blood vessels leading into the kidneys without affecting those carrying blood away. This could lead to increased pressure within the kidney’s filtering units, exacerbating existing damage.

While the study was observational and cannot definitively prove causation, the findings are considered clinically significant due to the widespread use of DCCBs. Lead researcher Dr. Timna Agur stressed that patients should not stop their medications without consulting their doctor. Further prospective studies and randomized controlled trials are necessary to confirm these observations and determine the safest and most effective blood pressure management strategies for individuals with DKD.

Lifestyle Factors Remain Crucial

Alongside medication, lifestyle modifications play a vital role in managing blood pressure and kidney health in individuals with type 2 diabetes. These include maintaining a healthy weight, reducing sodium intake, regular physical activity, consuming potassium-rich foods, limiting alcohol, managing stress, and ensuring adequate sleep. Regular monitoring of kidney function is also essential for early detection and intervention.

Sources

Advertisement